Why is Big Pharma So Scared of One Small Biotech Firm? 🏢

That’s why this company is our takeover target of the month. [FST Logo]( Hello Fellow American! [Want to hear about the best “hidden” opportunity on Wall Street?]( It isn’t cryptos or pot stocks like most investors think it is. What we’ve come to see as the best opportunity lies in the biotech sector. We’ve now seen a different biotech stock get taken over every 56 days… [Biden-]( So, I hope you’ve made good money with us! Today, I’ve decided to reveal some interesting information that most investors don’t know… In particular, I’m going to explain why these big mergers are happening. It started back in 1990, with the Human Genome Project (HGP). Their goal was to map the human genome. One of the benefits of this research was it allowed scientists to identify mutations linked to different types of cancer. After that, they were able to design new medications to address these mutations. [This is where the story gets interesting…]( Because 75% of the cancer drugs still being used are old drugs. The drug to treat Leukemia, for example, is Cytarbine. And Cytarbine was patented way back in 1960. And because it’s an old drug, patients have to suffer through a host of horrible side effects. These include rashes, vomiting, diarrhea, liver issues, bone marrow suppression, bleeding and ulcers of the mouth. Anybody who has dealt with cancer themselves or watched a loved one suffer knows how brutal the experience can be. This is why they say “the chemo will get you before the cancer does.” But the news does get better from here… [Because the HGP showed scientists a “NEW WAY” of fighting cancer. And they’ve been using data from the project to create new treatments.]( Why is this good for takeover investors? Worldwide, around $140 billion was spent on cancer therapies in 2018. And 75% of that was spent on the “OLD WAY” of doing things. Only 25% was spent on the “NEW WAY.” But how long can that last? Not very long. And that is a problem for Big Pharma companies. If they want to maintain their iron-clad grip on the industry, they need to either put together a whole new team to do research and hope they can make a drug that works… Or just buy out smaller biotech companies that are already busy designing these treatments. Recently, a small firm created a “NEW WAY” leukemia treatment. This is a big threat to Novartis and Bristol Myers. [And that’s why this company is our takeover target of the month.]( Just look at the past few months… Pfizer bought “NEW WAY” firm Array Biopharma at $48 a share…which was a 144% gain from our recommended price of $18.90. Glaxo bought Tesaro at $74.96…a big 93% gain from our recommended price of $38.51 Eli Lilly acquired Loxo Oncology for $234.66…a 78% gain from our recommended price of $131.02. Illumina picked up a diagnostic firm called Pacific Biosciences for $8…which was an 82% gain from our recommended price of $4.38. What’s the next “NEW WAY” company to get acquired? [Click here to find out who we predict will be taken over next…and why we think it has the potential to make millions for fast-acting investors.]( "The Buck Stops Here" Dylan Jovine Chairman Behind the Markets [Logo FST] You are receiving this e-mail because you have expressed an interest in the Financial Education niche on one of our landing pages. This email was sent to you by Flex Stock Trading on behalf of Event Horizon LLC. 435 N Dupont Hwy, Dover, DE, 19901, USA At FST Team, we keep an eye out for favorable opportunities we believe will interest our readers. The following is one such message from one of our colleagues that we think you'll appreciate. © 2024 All Rights Reserved. Flex Stock Trading [Terms Conditions]( [Privacy Policy]( [Unsubscribe](